Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | LDHA | P00338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8630523 | 0.92 | PTGS2 (0.50) | PTGS2PTGS1 | |
| SCHEMBL8629916 | 0.89 | PTGS2 (0.54) | PTGS2PTGS1CA9CA12CA1 | |
| SCHEMBL8634887 | 0.87 | PTGS2 (0.54) | PTGS2PTGS1CA9CA12CA1 | |
| SCHEMBL8633234 | 0.85 | PTGS2 (0.65) | PTGS2PTGS1CA9CA12CA1 | |
| SCHEMBL8631058 | 0.85 | PTGS2 (0.50) | PTGS2PTGS1CA9CA12CA1 | |
| SCHEMBL8631623 | 0.84 | PTGS2 (0.53) | PTGS2PTGS1CA9CA12CA1 | |
| SCHEMBL8630452 | 0.83 | PTGS2 (0.52) | PTGS2PTGS1CA9CA12CA1 | |
| SCHEMBL8634624 | 0.83 | PTGS2 (0.46) | PTGS2PTGS1CA9CA12CA1 | |
| SCHEMBL8631370 | 0.83 | PTGS2 (0.52) | PTGS2PTGS1CHRNA7 | |
| SCHEMBL8635115 | 0.83 | PTGS2 (0.52) | PTGS2PTGS1CHRNA7PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5756530-A | NON-STEROIDAL ANTIINFLAMMATORY AGENTS WITH REDUCED SIDE EFFECTS | G. D. SEARLE & CO. (US) | 1998-05-26 | — | — | US | disclosed |